Jun 14, 2024
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024    read more...
Jun 04, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference    read more...
May 24, 2024
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL    read more...
May 14, 2024
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024    read more...
May 08, 2024
BeiGene Reports First Quarter 2024 Financial Results and Business Updates    read more...
Apr 26, 2024
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report    read more...
Apr 24, 2024
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting    read more...
Apr 23, 2024
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer    read more...
Mar 14, 2024
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy    read more...
Mar 13, 2024
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation    read more...
Mar 12, 2024
Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night    read more...
Mar 07, 2024
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma    read more...
Mar 06, 2024
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024    read more...
Feb 29, 2024
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia    read more...
Feb 28, 2024
BeiGene to Present at Upcoming Investor Conferences    read more...
Feb 27, 2024
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA    read more...
Feb 26, 2024
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates    read more...
Feb 26, 2024
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer    read more...
Jan 23, 2024
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors    read more...
Dec 22, 2023
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)    read more...